Search

Your search keyword '"Nicolini, Franck E."' showing total 1,428 results
Start Over Author "Nicolini, Franck E."
1,428 results on '"Nicolini, Franck E."'

1. Health-related quality of life and symptoms of chronic myeloid leukemia patients after discontinuation of tyrosine kinase inhibitors: results from the EURO-SKI Trial

Author

Efficace, Fabio, Mahon, Francois-Xavier, Richter, Johan, Piciocchi, Alfonso, Cipriani, Marta, Nicolini, Franck E., Mayer, Jiri, Zackova, Daniela, Janssen, Jeroen J. W. M., Panayiotidis, Panayiotis, Vestergaard, Hanne, Koskenvesa, Perttu, Almeida, Antonio, Hjorth-Hansen, Henrik, Martinez-Lopez, Joaquin, Olsson-Strömberg, Ulla, Hochhaus, Andreas, Berger, Marc G., Etienne, Gabriel, Klamova, Hana, Faber, Edgar, Rousselot, Philippe, Pfirrmann, Markus, and Saussele, Susanne

Published
2024
Full Text
View/download PDF

3. Management and outcome of patients with chronic myeloid leukemia in blast phase in the tyrosine kinase inhibitor era – analysis of the European LeukemiaNet Blast Phase Registry

Author

Brioli, Annamaria, Lomaia, Elza, Fabisch, Christian, Sacha, Tomasz, Klamova, Hana, Morozova, Elena, Golos, Aleksandra, Ernst, Philipp, Olsson-Stromberg, Ulla, Zackova, Daniela, Nicolini, Franck E., Bao, Han, Castagnetti, Fausto, Patkowska, Elzbieta, Mayer, Jiri, Hirschbühl, Klaus, Podgornik, Helena, Paczkowska, Edyta, Parry, Anne, Ernst, Thomas, Voskanyan, Astghik, Szczepanek, Elzbieta, Saussele, Susanne, Franke, Georg-Nikolaus, Kiani, Alexander, Faber, Edgar, Krause, Stefan, Casado, Luis Felipe, Lewandowski, Krzysztof, Eder, Matthias, Anhut, Peter, Gil, Justyna, Südhoff, Thomas, Hebart, Holger, Heibl, Sonja, Pfirrmann, Markus, Hochhaus, Andreas, and Lauseker, Michael

Published
2024
Full Text
View/download PDF

4. Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry

Author

Chelysheva, Ekaterina, Apperley, Jane, Turkina, Anna, Yassin, Mohamed A., Rea, Delphine, Nicolini, Franck E., Barraco, Daniela, Kazakbaeva, Khamida, Saliev, Sukhrob, Abulafia, Adi Shacham, Al-Kindi, Salam, Byrne, Jennifer, Robertson, Harry F., Cerrano, Marco, Shmakov, Roman, Polushkina, Evgenia, de Fabritiis, Paolo, Trawinska, Malgorzata Monika, and Abruzzese, Elisabetta

Published
2024
Full Text
View/download PDF

5. Correction: Chronic myeloid leukemia diagnosed in pregnancy: management and outcome of 87 patients reported to the European LeukemiaNet international registry

Author

Chelysheva, Ekaterina, Apperley, Jane, Turkina, Anna, Yassin, Mohamed A., Rea, Delphine, Nicolini, Franck E., Barraco, Daniela, Kazakbaeva, Khamida, Saliev, Sukhrob, Abulafia, Adi Shacham, Al-Kindi, Salam, Byrne, Jennifer, Robertson, Harry F., Cerrano, Marco, Shmakov, Roman, Polushkina, Evgenia, de Fabritiis, Paolo, Trawinska, Malgorzata Monika, and Abruzzese, Elisabetta

Published
2024
Full Text
View/download PDF

7. Specific, targetable interactions with the microenvironment influence imatinib-resistant chronic myeloid leukemia

Author

Kumar, Rahul, Pereira, Raquel S, Zanetti, Costanza, Minciacchi, Valentina R, Merten, Maximilian, Meister, Melanie, Niemann, Julian, Dietz, Marina S, Rüssel, Nina, Schnütgen, Frank, Tamai, Minori, Akahane, Koshi, Inukai, Takeshi, Oellerich, Thomas, Kvasnicka, Hans Michael, Pfeifer, Heike, Nicolini, Franck E, Heilemann, Mike, Van Etten, Richard A, and Krause, Daniela S

Subjects
Biomedical and Clinical Sciences, Oncology and Carcinogenesis, Cancer, Stem Cell Research, Hematology, Rare Diseases, 5.1 Pharmaceuticals, Development of treatments and therapeutic interventions, 2.1 Biological and endogenous factors, Aetiology, Animals, Drug Resistance, Neoplasm, Fibronectins, Focal Adhesion Protein-Tyrosine Kinases, Fusion Proteins, bcr-abl, Humans, Imatinib Mesylate, Imidazoles, Integrin beta3, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mice, Protein Serine-Threonine Kinases, Pyridazines, Clinical Sciences, Immunology, Cardiovascular medicine and haematology, Clinical sciences, Oncology and carcinogenesis
Abstract

Therapy resistance in leukemia may be due to cancer cell-intrinsic and/or -extrinsic mechanisms. Mutations within BCR-ABL1, the oncogene giving rise to chronic myeloid leukemia (CML), lead to resistance to tyrosine kinase inhibitors (TKI), and some are associated with clinically more aggressive disease and worse outcome. Using the retroviral transduction/transplantation model of CML and human cell lines we faithfully recapitulate accelerated disease course in TKI resistance. We show in various models, that murine and human imatinib-resistant leukemia cells positive for the oncogene BCR-ABL1T315I differ from BCR-ABL1 native (BCR-ABL1) cells with regards to niche location and specific niche interactions. We implicate a pathway via integrin β3, integrin-linked kinase (ILK) and its role in deposition of the extracellular matrix (ECM) protein fibronectin as causative of these differences. We demonstrate a trend towards a reduced BCR-ABL1T315I+ tumor burden and significantly prolonged survival of mice with BCR-ABL1T315I+ CML treated with fibronectin or an ILK inhibitor in xenogeneic and syngeneic murine transplantation models, respectively. These data suggest that interactions with ECM proteins via the integrin β3/ILK-mediated signaling pathway in BCR-ABL1T315I+ cells differentially and specifically influence leukemia progression. Niche targeting via modulation of the ECM may be a feasible therapeutic approach to consider in this setting.

Published
2020

9. The CML experience to elucidate the role of innate T-cells as effectors in the control of residual cancer cells and as potential targets for cancer therapy.

Author

Decroos, Amandine, Meddour, Sarah, Demoy, Marine, Piccirilli, Nathalie, Rousselot, Philippe, Nicolini, Franck E., Ragot, Stéphanie, Gombert, Jean-Marc, Herbelin, André, Barbarin, Alice, and Cayssials, Emilie

Subjects
TRANSCRIPTION factors, KILLER cells, CHRONIC myeloid leukemia, T cells, TERMINATION of treatment, PERFORINS
Abstract

Considering the general view that unconventional immune effectors play a major role in antitumor immunity, we recently postulated that the distinct new innate CD8 T-cell pool (co-expressing the transcription factor Eomesodermin and innate markers such as KIR/NKG2A) may counteract tumor cells, and thereby be potential target for cancer therapy. Here, to test this assumption, we used successfully targeted anti-leukemic therapy discontinuation (TFR) in chronic myeloid leukemia (CML). Numerical and functional status of innate CD8 T-cells, iNKT cells and γδ T-cells, in comparison with NK cells, was compared longitudinally between non-relapsed patients (i.e., with > 12 months TFR) and relapsed patients (i.e., who experienced molecular recurrence during the first 12 months after TKI cessation) in a prospective pilot cohort (n=32), starting from treatment discontinuation (D0). Perforin, a key cytotoxic immune player, was expressed in a significantly higher proportion of both innate CD8 T-cell and NK-cell subsets in non-relapsed patients, compared with relapsed patients at D0. In parallel, we assessed the expression of PD-1, an exhaustion marker used as target in cancer therapy. For all T-cell subsets, surface-expression level of PD-1 decreased in non-relapsed patients compared with relapsed patients at D0. This was particularly the case when considering iNKT cells for which surface-expression level of PD-1 even decreased relative to healthy control subjects. Lastly, we found a negative correlation between the proportion of innate CD8 T-cells expressing PD-1 and those expressing perforin in non-relapsed patients at D0. The fact that this was not the case in conventional CD8 T-cells is compatible with a reprogrammed effector profile preferentially targeting innate CD8 T-cells in non-relapsed patients. All in all, our results highlight NK cells and innate CD8 T-cells harboring cytotoxic content, as well as global downregulation of PD-1-expression on effector T-cells, as potential predictive functional signatures for successful TFR in CML. Considering innate CD8 T-cells, further investigations are needed to determine whether their possible contributory role in cancer surveillance in CML could be extended to other cancers, and also whether their targeting by immune cheek-point inhibitors could enhance their anti-tumoral functions. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Results of ponatinib as frontline therapy for chronic myeloid leukemia in chronic phase.

Author

Haddad, Fadi G., Sasaki, Koji, Nasr, Lewis, Short, Nicholas J., Kadia, Tapan, Dellasala, Sara, Cortes, Jorge, Nicolini, Franck E., Issa, Ghayas C., Jabbour, Elias, and Kantarjian, Hagop

Subjects
CHRONIC myeloid leukemia, PROTEIN-tyrosine kinase inhibitors, CARDIOTOXICITY, OVERALL survival, SURVIVAL rate
Abstract

Background: Ponatinib is a third‐generation BCR::ABL1 tyrosine kinase inhibitor (TKI) with robust activity in Philadelphia chromosome–positive leukemias. Herein, we report the long‐term follow‐up of the phase 2 trial of ponatinib in chronic myeloid leukemia in chronic phase. Methods: Patients received ponatinib 30 to 45 mg/day. The primary end point was the rate of 6‐month complete cytogenetic response (CCyR). The study was held in June 2014 because of the risk of cardiovascular toxicity, requiring patients to change TKI. Results: Fifty‐one patients were treated with ponatinib (median dose, 45 mg/day). Median age was 48 years (range, 21–75); 30 (59%) had baseline cardiovascular comorbidities. Median treatment duration was 13 months (range, 2–25). Fourteen patients (28%) discontinued ponatinib because of toxicities, 36 (71%) after the Food and Drug Administration warning/study closure, and one for noncompliance. Dasatinib was the most frequently chosen second‐line TKI (n = 34; 66%). Among 46 patients evaluable at 6 months, 44 (96%) achieved CCyR, 37 (80%) major molecular response, 28 (61%) MR4, and 21 (46%) MR4.5. The cumulative 6‐month rates of CCyR, major molecular response, MR4, and MR4.5 were 96%, 78%, 50%, and 36%, respectively. Durable MR4 ≥24 or ≥60 months was observed in 67% and 51% of patients, respectively. The 24‐month event‐free survival rate was 97%. After a median follow‐up of 128 months, the 10‐year overall survival rate was 90%. Eight patients (16%) had serious grade 2 to 3 cardiovascular adverse events, leading to permanent discontinuation in five (10%). Conclusion: Ponatinib yielded high cytogenetic and molecular responses in newly diagnosed chronic myeloid leukemia in chronic phase. Its use in the frontline setting is hindered by arterio‐/vaso‐occlusive and other severe toxicities. Treatment with ponatinib in the frontline setting of chronic myeloid leukemia in chronic phase was associated with high molecular response rates, with 12‐month cumulative rates of major molecular response and MR4 of 82% and 72%, respectively. However, it was associated with an increased incidence of toxicity, in particular serious grade 2‐3 cardiovascular adverse events in 16% of the patients. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

11. European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia : Final Analysis and Novel Prognostic Factors for Treatment-Free Remission

Author

Mahon, Francois-Xavier, Pfirrmann, Markus, Dulucq, Stephanie, Hochhaus, Andreas, Panayiotidis, Panayiotis, Almeida, Antonio, Mayer, Jiri, Hjorth-Hansen, Henrik, Janssen, Jeroen J. W. M., Mustjoki, Satu, Martinez-Lopez, Joaquin, Vestergaard, Hanne, Ehrencrona, Hans, Polakova, Katerina Machova, Olsson-Strömberg, Ulla, Ossenkoppele, Gert, Berger, Marc G., Etienne, Gabriel, Dengler, Jolanta, Bruemmendorf, Tim H., Burchert, Andreas, Rea, Delphine, Rousselot, Philippe, Nicolini, Franck E., Hofmann, Wolf-Karsten, Richter, Johan, Saussele, Susanne, Mahon, Francois-Xavier, Pfirrmann, Markus, Dulucq, Stephanie, Hochhaus, Andreas, Panayiotidis, Panayiotis, Almeida, Antonio, Mayer, Jiri, Hjorth-Hansen, Henrik, Janssen, Jeroen J. W. M., Mustjoki, Satu, Martinez-Lopez, Joaquin, Vestergaard, Hanne, Ehrencrona, Hans, Polakova, Katerina Machova, Olsson-Strömberg, Ulla, Ossenkoppele, Gert, Berger, Marc G., Etienne, Gabriel, Dengler, Jolanta, Bruemmendorf, Tim H., Burchert, Andreas, Rea, Delphine, Rousselot, Philippe, Nicolini, Franck E., Hofmann, Wolf-Karsten, Richter, Johan, and Saussele, Susanne

Abstract

Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported.The European Stop Kinase Inhibitors (EURO-SKI) study is the largest clinical trial for investigating the cessation of tyrosine kinase inhibitors (TKIs) in patients with chronic myeloid leukemia in stable deep molecular remission (DMR). Among 728 patients, 434 patients (61%; 95% CI, 57 to 64) remained in major molecular response (MMR) at 6 months and 309 patients of 678 (46%; 95% CI, 42 to 49) at 36 months. Duration of TKI treatment and DMR before TKI stop were confirmed as significant factors for the prediction of MMR loss at 6 months. In addition, the type of BCR::ABL1 transcript was identified as a prognostic factor. For late MMR losses after 6 months, TKI treatment duration, percentage of blasts in peripheral blood, and platelet count at diagnosis were significant factors in multivariate analysis. For the entire study period of 36 months, multiple logistic regression models confirmed duration of treatment, blasts, and transcript type as independent factors for MMR maintenance. In addition to the duration of treatment, transcript type as well as blasts in peripheral blood at diagnosis should be considered as important factors to predict treatment-free remission.

Published
2024
Full Text
View/download PDF

13. Effect of low-level BCR-ABL1 kinase domain mutations identified by next-generation sequencing in patients with chronic myeloid leukaemia: a population-based study

Author

Kizilors, Aytug, Crisà, Elena, Lea, Nicholas, Passera, Roberto, Mian, Syed, Anwar, Jamal, Best, Steve, Nicolini, Franck E, Ireland, Robin, Aldouri, Maadh, Pocock, Christopher, Corbett, Tim, Gale, Richard, Bart-Smith, Emily, Weston-Smith, Simon, Wykes, Clare, Kulasekararaj, Austin, Jackson, Sophie, Harrington, Patrick, McLornan, Donal, Raj, Kavita, Pagliuca, Antonio, Mufti, Ghulam J, and de Lavallade, Hugues

Published
2019
Full Text
View/download PDF

14. Kinetics of molecular recurrence after tyrosine kinase inhibitor cessation in chronic phase chronic myelogenous leukaemia patients

Author

Alcazer, Vincent, primary, Morisset, Stéphane, additional, Rea, Delphine, additional, Legros, Laurence, additional, Dulucq, Stéphanie, additional, Hayette, Sandrine, additional, Cayuela, Jean‐Michel, additional, Huguet, Françoise, additional, Mahon, François‐Xavier, additional, Etienne, Gabriel, additional, and Nicolini, Franck E., additional

Published
2024
Full Text
View/download PDF

15. Ponatinib evaluation and safety in real-life chronic myelogenous leukemia patients failing more than two tyrosine kinase inhibitors: the PEARL observational study

Author

Heiblig, Maël, Rea, Delphine, Chrétien, Marie-Lorraine, Charbonnier, Aude, Rousselot, Philippe, Coiteux, Valérie, Escoffre-Barbe, Martine, Dubruille, Viviane, Huguet, Françoise, Cayssials, Emilie, Hermet, Eric, Guerci-Bresler, Agnès, Amé, Shanti, Sackmann-Sala, Lucila, Roy, Lydia, Sobh, Mohamad, Morisset, Stéphane, Etienne, Gabriel, and Nicolini, Franck E.

Published
2018
Full Text
View/download PDF

16. Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia: final 5-year results of the phase 2 PACE trial

Author

Cortes, Jorge E., Kim, Dong-Wook, Pinilla-Ibarz, Javier, le Coutre, Philipp D., Paquette, Ronald, Chuah, Charles, Nicolini, Franck E., Apperley, Jane F., Khoury, H. Jean, Talpaz, Moshe, DeAngelo, Daniel J., Abruzzese, Elisabetta, Rea, Delphine, Baccarani, Michele, Müller, Martin C., Gambacorti-Passerini, Carlo, Lustgarten, Stephanie, Rivera, Victor M., Haluska, Frank G., Guilhot, François, Deininger, Michael W., Hochhaus, Andreas, Hughes, Timothy P., Shah, Neil P., and Kantarjian, Hagop M.

Published
2018
Full Text
View/download PDF

17. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

Author

Ossenkoppele, Gert, Pagoni, Maria N., Söderlund, Stina, Escoffre-Barbe, Martine, Etienne, Gabriel, Dengler, Jolanta, Huguet, Francoise, von Bubnoff, Nikolas, Klamova, Hana, Faber, Edgar, Guilhot, Francois, Lotfi, Kourosh, Rea, Delphine, Brümmendorf, Tim H., de Greef, Gorgine E., Stenke, Leif, Nicolini, Franck E., Legros, Laurence, Burchert, Andreas, Voglova, Jaroslava, Charbonnier, Aude, Gyan, Emmanuel, Kunzmann, Volker, Westerweel, Peter E., Saussele, Susanne, Richter, Johan, Guilhot, Joelle, Gruber, Franz X, Hjorth-Hansen, Henrik, Almeida, Antonio, Janssen, Jeroen J W M, Mayer, Jiri, Koskenvesa, Perttu, Panayiotidis, Panayiotis, Olsson-Strömberg, Ulla, Martinez-Lopez, Joaquin, Rousselot, Philippe, Vestergaard, Hanne, Ehrencrona, Hans, Kairisto, Veli, Machová Poláková, Katerina, Müller, Martin C, Mustjoki, Satu, Berger, Marc G, Fabarius, Alice, Hofmann, Wolf-Karsten, Hochhaus, Andreas, Pfirrmann, Markus, and Mahon, Francois-Xavier

Published
2018
Full Text
View/download PDF

19. Interleukin 10 (IL10) and IL15 Significantly Decreased in Chronic Myeloid Leukemia Patients Presenting with Tyrosine Kinase Inhibitor (TKI) Withdrawal Syndrome (TWS). Results from the Prospective, Explorative and Multicenter « Kiwis » Study Designed for TWS. Clinicaltrial.Gov ID: NCT03996096; Study Number: 18-206

Author

Johnson-Ansah, Hyacinthe A., primary, Briant, Anaïs, additional, Charbonnier, Amandine, additional, Cambier, Nathalie, additional, Damaj, Gandhi Laurent, additional, Lenain, Pascal, additional, Henry, Alexandra, additional, Parienti, Jean-Jacques, additional, Guenet, David, additional, GAC Besnard, Anne-Claire, additional, Delapierre, Baptiste, additional, Nicolini, Franck E., additional, Le Mauff, Brigitte, additional, and Berger, Marc G., additional

Published
2023
Full Text
View/download PDF

20. Identification of Individual Risk Factors for Treatment Free Remission (TFR) Failure in Chronic Phase Chronic Myeloid Leukemia (CP-CML) Patients: Predictive Models Developed on a Nationwide Clinical and Claim Database

Author

Chassetuillier, Jules, primary, Benmerad, Meriem, additional, Lecoq, Pierre-Louis, additional, Favier, Romain, additional, Trancart, Matthieu, additional, Hayette, Sandrine, additional, Alcazer, Vincent, additional, Bouvier, Christophe, additional, Bollard, Julien, additional, Lajoinie, Audrey, additional, and Nicolini, Franck E., additional

Published
2023
Full Text
View/download PDF

21. Treatment-Free Remission after Ponatinib Cessation in Chronic Phase (CP) Chronic Myeloid Leukemia (CML) Patients. the Ponastop Observational Study

Author

Nicolini, Franck E., primary, Abruzzese, Elisabetta, additional, Roth-Guepin, Gabrielle, additional, Abi-Tayeh, Rami, additional, Alcazer, Vincent, additional, Hayette, Sandrine, additional, Morisset, Stéphane, additional, Huguet, Françoise, additional, Iezza, Miriam, additional, Castagnetti, Fausto, additional, and Rea, Delphine, additional

Published
2023
Full Text
View/download PDF

22. POSTER: CML-310 Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data

Author

Müller, Martin C., primary, Cortes, Jorge, additional, Chuah, Charles, additional, DeAngelo, Daniel J., additional, Deininger, Michael, additional, Guilhot, François, additional, Hughes, Timothy, additional, Nicolini, Franck E., additional, Pinilla-Ibarz, Javier, additional, Rea, Delphine, additional, Rosti, Gianantonio, additional, Shah, Neil P., additional, Talpaz, Moshe, additional, Lu, Vickie, additional, Padukkavidana, Thihan, additional, and Kantarjian, Hagop M., additional

Published
2023
Full Text
View/download PDF

23. CML-310 Early Cytogenetic or Molecular Landmark Response to Ponatinib Treatment Predicts Outcomes in Heavily Pretreated Patients With Chronic-Phase Chronic Myeloid Leukemia (CP-CML) in PACE: 5-Year Data

Author

Müller, Martin C., primary, Cortes, Jorge, additional, Chuah, Charles, additional, DeAngelo, Daniel J., additional, Deininger, Michael, additional, Guilhot, François, additional, Hughes, Timothy, additional, Nicolini, Franck E., additional, Pinilla-Ibarz, Javier, additional, Rea, Delphine, additional, Rosti, Gianantonio, additional, Shah, Neil P., additional, Talpaz, Moshe, additional, Lu, Vickie, additional, Padukkavidana, Thihan, additional, and Kantarjian, Hagop M., additional

Published
2023
Full Text
View/download PDF

25. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

Author

Rea, Delphine, Nicolini, Franck E., Tulliez, Michel, Guilhot, François, Guilhot, Joelle, Guerci-Bresler, Agnès, Gardembas, Martine, Coiteux, Valérie, Guillerm, Gaelle, Legros, Laurence, Etienne, Gabriel, Pignon, Jean-Michel, Villemagne, Bruno, Escoffre-Barbe, Martine, Ianotto, Jean-Christophe, Charbonnier, Aude, Johnson-Ansah, Hyacinthe, Noel, Marie-Pierre, Rousselot, Philippe, and Mahon, François-Xavier

Published
2017
Full Text
View/download PDF

28. Risk of progression in chronic phase‐chronic myeloid leukemia patients eligible for tyrosine kinase inhibitor discontinuation: Final analysis of the TFR‐PRO study

Author

Zambrotta, Giovanni Paolo Maria, primary, Nicolini, Franck E., additional, Assouline, Sarit, additional, Busque, Lambert, additional, Pungolino, Ester, additional, Abruzzese, Elisabetta, additional, Miggiano, Maria Cristina, additional, Elena, Chiara, additional, Alvarez‐Larran, Alberto, additional, Triguero, Ana, additional, Iurlo, Alessandra, additional, Bucelli, Cristina, additional, Cerrano, Marco, additional, Capodanno, Isabella, additional, Lunghi, Francesca, additional, le Coutre, Philipp, additional, Galimberti, Sara, additional, Caocci, Giovanni, additional, Maffioli, Margherita, additional, Stagno, Fabio, additional, Saussele, Susanne, additional, Piazza, Rocco, additional, Druker, Brian J., additional, Fava, Carmen, additional, Guglielmana, Veronica, additional, Colombo, Federica, additional, Antolini, Laura, additional, and Gambacorti‐Passerini, Carlo, additional

Published
2023
Full Text
View/download PDF

29. P667: RISK OF PROGRESSION IN CHRONIC PHASE-CHRONIC MYELOID LEUKEMIA PATIENTS ELIGIBLE FOR TYROSINE KINASE INHIBITOR DISCONTINUATION: FINAL ANALYSIS OF THE TFR-PRO STUDY

Author

Paolo Maria Zambrotta, Giovanni, primary, Assouline, Sarit, additional, Nicolini, Franck E., additional, Abruzzese, Elisabetta, additional, Pungolino, Ester, additional, Cristina Miggiano, Maria, additional, Elena, Chiara, additional, Alvarez Larran, Alberto, additional, Triguero Moreno, Ana, additional, Iurlo, Alessandra, additional, Bucelli, Cristina, additional, Lunghi, Francesca, additional, Capodanno, Isabella, additional, Maffioli, Margherita, additional, Galimberti, Sara, additional, Caocci, Giovanni, additional, Stagno, Fabio, additional, Saussele, Susanne, additional, Fava, Carmen, additional, Le Coutre, Philipp, additional, Bonifacio, Massimiliano, additional, Guglielmana, Veronica, additional, Colombo, Federica, additional, Antolinni, Laura, additional, and Gambacorti-Passerini, Carlo, additional

Published
2023
Full Text
View/download PDF

30. Ponatinib versus imatinib for newly diagnosed chronic myeloid leukaemia: an international, randomised, open-label, phase 3 trial

Author

Lipton, Jeffrey H, Chuah, Charles, Guerci-Bresler, Agnès, Rosti, Gianantonio, Simpson, David, Assouline, Sarit, Etienne, Gabriel, Nicolini, Franck E, le Coutre, Philipp, Clark, Richard E, Stenke, Leif, Andorsky, David, Oehler, Vivian, Lustgarten, Stephanie, Rivera, Victor M, Clackson, Timothy, Haluska, Frank G, Baccarani, Michele, Cortes, Jorge E, Guilhot, François, Hochhaus, Andreas, Hughes, Timothy, Kantarjian, Hagop M, Shah, Neil P, Talpaz, Moshe, and Deininger, Michael W

Published
2016
Full Text
View/download PDF

31. Compound mutations in BCR-ABL1 are not major drivers of primary or secondary resistance to ponatinib in CP-CML patients

Author

Deininger, Michael W., Hodgson, J. Graeme, Shah, Neil P., Cortes, Jorge E., Kim, Dong-Wook, Nicolini, Franck E., Talpaz, Moshe, Baccarani, Michele, Müller, Martin C., Li, Jin, Parker, Wendy T., Lustgarten, Stephanie, Clackson, Tim, Haluska, Frank G., Guilhot, Francois, Kantarjian, Hagop M., Soverini, Simona, Hochhaus, Andreas, Hughes, Timothy P., Rivera, Victor M., and Branford, Susan

Published
2016
Full Text
View/download PDF

32. Efficacy and safety of nilotinib in chronic myeloid leukaemia patients who failed to achieve a treatment‐free remission period after imatinib discontinuation: Results of the French Nilo post‐STIM study

Author

Dulucq, Stéphanie, primary, Rigal‐Huguet, Françoise, additional, Nicolini, Franck E., additional, Cony‐Makhoul, Pascale, additional, Escoffre‐Barbe, Martine, additional, Gardembas, Martine, additional, Legros, Laurence, additional, Rousselot, Philippe, additional, Liu, Jixing, additional, Rea, Delphine, additional, De Mas, Véronique, additional, Hayette, Sandrine, additional, Raynaud, Sophie, additional, Lacoste‐Roussillon, Caroline, additional, Robbesyn, Fanny, additional, Klein, Emilie, additional, Morisset, Stéphane, additional, Mahon, François‐Xavier, additional, and Etienne, Gabriel, additional

Published
2023
Full Text
View/download PDF

35. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

Author

Zabriskie, Matthew S., Eide, Christopher A., Tantravahi, Srinivas K., Vellore, Nadeem A., Estrada, Johanna, Nicolini, Franck E., Khoury, Hanna J., Larson, Richard A., Konopleva, Marina, Cortes, Jorge E., Kantarjian, Hagop, Jabbour, Elias J., Kornblau, Steven M., Lipton, Jeffrey H., Rea, Delphine, Stenke, Leif, Barbany, Gisela, Lange, Thoralf, Hernández-Boluda, Juan-Carlos, Ossenkoppele, Gert J., Press, Richard D., Chuah, Charles, Goldberg, Stuart L., Wetzler, Meir, Mahon, Francois-Xavier, Etienne, Gabriel, Baccarani, Michele, Soverini, Simona, Rosti, Gianantonio, Rousselot, Philippe, Friedman, Ran, Deininger, Marie, Reynolds, Kimberly R., Heaton, William L., Eiring, Anna M., Pomicter, Anthony D., Khorashad, Jamshid S., Kelley, Todd W., Baron, Riccardo, Druker, Brian J., Deininger, Michael W., and O’Hare, Thomas

Published
2014
Full Text
View/download PDF

38. Chronic Myeloid Leukemia Diagnosed during Pregnancy: How to Manage? Description of 86 Cases from ELN International Registry

Author

Chelysheva, Ekaterina Yu., primary, Turkina, Anna, additional, Apperley, Jane F., additional, Yassin, Mohamed A, additional, Rea, Delphine, additional, Nicolini, Franck E., additional, Barraco, Daniela, additional, Kotlyarchuk, Konstantin, additional, Kazakbaeva, Khamida, additional, Saliev, Sukhrob, additional, Shacham, Adi, additional, Kim, Dong-Wook, additional, Al-Kindi, Salam, additional, Ganeva, Penka, additional, Shmakov, Roman, additional, Byrne, Jennifer, additional, Robertson, Harry, additional, Marco, Cerrano, additional, Polushkina, Evgenia, additional, Trawinska, Malgorzata Monika, additional, and Abruzzese, Elisabetta, additional

Published
2022
Full Text
View/download PDF

39. Treatment Patterns, Tolerance, and Clinical Response of Chronic Phase Chronic Myeloid Leukemia (CML-CP) Patients (Including Those Harboring the T315I Mutation) Experiencing Multiple Tyrosine Kinase Inhibitor Failure: A Multi-Center Retrospective Chart Review Analysis

Author

Nicolini, Franck E., primary, Huguet, Francoise, additional, Huynh, Lynn, additional, Xu, Churong, additional, Bouvier, Christophe, additional, Yocolly, Aurore, additional, and Etienne, Gabriel, additional

Published
2022
Full Text
View/download PDF

40. Risk of Progression in Chronic Phase-Chronic Myeloid Leukemia (CML) Patients Eligible for Tyrosine Kinase Inhibitor Discontinuation: The Tfr-PRO Study

Author

Zambrotta, Giovanni, primary, Assouline, Sarit, additional, Nicolini, Franck E., additional, Abruzzese, Elisabetta, additional, Miggiano, Maria Cristina, additional, Elena, Chiara, additional, Alvarez-Larran, Alberto, additional, Triguero, Ana, additional, Iurlo, Alessandra, additional, Bucelli, Cristina, additional, Lunghi, Francesca, additional, Capodanno, Isabella, additional, Maffioli, Margherita, additional, Galimberti, Sara, additional, Caocci, Giovanni, additional, Stagno, Fabio, additional, Saussele, Susanne, additional, Fava, Carmen, additional, le Coutre, Philipp, additional, Bonifacio, Massimiliano, additional, Guglielmana, Veronica, additional, Colombo, Federica, additional, Antolini, Laura, additional, and Gambacorti-Passerini, Carlo, additional

Published
2022
Full Text
View/download PDF

41. Efficacy of Ropeginterferon Alpha 2b in Inducing Treatment Free Remission in Chronic Myeloid Leukemia - an International, Randomized Phase III Trial (ENDURE, CML-IX) of the German CML-Study Group

Author

Burchert, Andreas, primary, Saussele, Susanne, additional, Michel, Christian, additional, Metzelder, Stephan K, additional, Hochhaus, Andreas, additional, Gattermann, Norbert, additional, Crysandt, Martina, additional, Schafhausen, Philippe, additional, Bormann, Matthias, additional, Radsak, Markus P., additional, Guerci-Bresler, Agnès, additional, Illmer, Thomas, additional, Goebeler, Maria E, additional, Herhaus, Peter, additional, Teichmann, Lino L., additional, Franke, Georg-Nikolaus, additional, Lang, Fabian, additional, Krause, Stefan W., additional, Möhle, Robert, additional, Klausmann, Martine, additional, Stegelmann, Frank, additional, Lutz, Christoph, additional, Etienne, Gabriel, additional, Stoltefuß, Andrea, additional, Göthert, Joachim R, additional, Ernst, Thomas, additional, Neubauer, Andreas, additional, Hehlmann, Rüdiger, additional, Aminossadati, Behnaz, additional, Wittenberg, Michael, additional, Pfirrmann, Markus, additional, Schade-Brittinger, Carmen, additional, le Coutre, Philipp, additional, and Nicolini, Franck E., additional

Published
2022
Full Text
View/download PDF

42. A Risk Model for CML Patients with COVID-19: Importance of Molecular Response in the Context of Age, Comorbidities and Country Income

Author

Radich, Jerald P., primary, Kok, Chung Hoow, additional, Chelysheva, Ekaterina Yu., additional, Cortes, Jorge E., additional, Jiang, Qian, additional, Mauro, Michael, additional, Milojkovic, Dragana, additional, Moiraghi, Beatriz, additional, Nicolini, Franck E., additional, Ongondi, Matilda, additional, Pagnano, Katia B, additional, Žácková, Daniela, additional, Rea, Delphine, additional, Evans, Nicola, additional, and Hughes, Timothy, additional

Published
2022
Full Text
View/download PDF

43. Treatment-Free Remission in Chronic Phase Chronic Myeloid Leukemia Patients Treated with Nilotinib Front-Line, in Real-Life Conditions: Influence of Switching to Another TKI Prior to Cessation.

Author

Nicolini, Franck E., primary, Alcazer, Vincent, additional, Cony-Makhoul, Pascale, additional, Dulucq, Stéphanie, additional, Hayette, Sandrine, additional, Morisset, Stéphane, additional, Parat, Rachel, additional, Bouvier, Christophe, additional, and Etienne, Gabriel, additional

Published
2022
Full Text
View/download PDF

44. In silico and Functional Studies for Classification of EPAS1/HIF2A Genetic Variants Identified in Patients with Erythrocytosis

Author

Karaghiannis, Valéna, primary, Maric, Darko, additional, Garrec, Céline, additional, Maaziz, Nada, additional, Buffet, Alexandre, additional, Antunes, Vincent, additional, le Roy, Amandine, additional, Airaud, Fabrice, additional, Aral, Bernard, additional, Schmitt, Loic, additional, Corbineau, Sébastien, additional, Mansour-Hendili, Lamisse, additional, Lesieur, Valentine, additional, Rimbert, Antoine, additional, Laporte, Fabien, additional, Delamare, Marine, additional, Bezieau, Stephane, additional, Cassinat, Bruno, additional, Galactéros, Frédéric, additional, Gimenez-Roqueplo, Anne-Paule, additional, Burnichon, Nelly, additional, Cario, Holger, additional, Wijk, Richard van, additional, Bento, Celeste, additional, Blouet, Anaise, additional, Bouteloup, Juliette, additional, Boyer perrard, Françoise, additional, Bruce, Aisha Aiko, additional, Cayssials, Emilie, additional, Casadevall, Nicole, additional, Cherel, Brieuc, additional, Couec, Marielaure, additional, Drevon, Louis, additional, Dumesnil, Cecile, additional, Lamy De La Chapelle, Thierry, additional, Gambart, Marion, additional, Garcon, Loic, additional, Granel, Brigitte, additional, Hirsch, Pierre, additional, Lahary, Agnès, additional, Mejri, Amira, additional, Meunier, Sandrine, additional, Nicolini, Franck E., additional, Raffoux, Emmanuel, additional, Ranta, Dana, additional, Schleinitz, Nicolas, additional, Valentin, Jean Baptiste, additional, Wemeau, Mathieu, additional, Girodon, Francois, additional, Hoogewijs, David, additional, Gardie, Betty, additional, and Hermine, Olivier, additional

Published
2022
Full Text
View/download PDF

45. Impact of the COVID-19 Epidemic on Patients with Myeloproliferative Neoplasia: The French Prospective Observational Study Covim

Author

Legros, Laurence, primary, Boyer perrard, Françoise, additional, Ranta, Dana, additional, Roy, Lydia, additional, Ojeda-Uribe, Mario, additional, Giraudier, Stephane, additional, Parquet, Nathalie, additional, Ianotto, Jean Christophe, additional, Wemeau, Mathieu, additional, Plantier, Isabelle, additional, Nicolini, Franck E., additional, Lippert, Eric, additional, Cony-Makhoul, Pascale, additional, Barraco, Fiorenza, additional, Stalnikiewicz, Laure, additional, Garban, Frederic, additional, Dupriez, Brigitte, additional, Girodon, Francois, additional, Brignier, Anne, additional, Arkam, Yazid, additional, Meunier, Mathieu, additional, James, Chloe, additional, Rolland-Neyret, Valérie, additional, Ugo, Valerie, additional, Morel, Pierre, additional, Bene, Marie C, additional, and Kiladjian, Jean-Jacques, additional

Published
2022
Full Text
View/download PDF

46. Efficacy and Safety of Vodobatinib in Patients (pts) with Chronic Phase Philadelphia Positive Chronic Myeloid Leukemia (Ph+ CML): A Sub Group Analysis By Lines of Tyrosine Kinase Inhibitor (TKI) Therapy

Author

Cortes, Jorge E., primary, Saikia, Tapan, additional, Kim, Dong-Wook, additional, Alvarado, Yesid, additional, Nicolini, Franck E., additional, Rathnam, Krishnakumar, additional, Khattry, Navin, additional, Punatar, Sachin, additional, Apperley, Jane F., additional, Charbonnier, Aude, additional, Deininger, Michael, additional, de Lavallade, Hugues, additional, Granacher, Nikki, additional, Gambacorti-Passerini, Carlo, additional, Lucchesi, Alessandro, additional, Mauro, Michael, additional, Vandenberghe, Peter, additional, Verhoef, Gregor, additional, Whiteley, Andrew R., additional, Nag, Arijit, additional, Apte, Shashikant, additional, Yao, Siu-Long, additional, Inamdar, Sandeep, additional, Dillu, Ruchika Irene, additional, Sreenivasan, Jayasree, additional, and Chimote, Geetanjali, additional

Published
2022
Full Text
View/download PDF

47. Treatment and Disease Characteristics of Chronic Myeloid Leukemia in Blast Crisis: The European Leukemianet Blast Crisis Registry

Author

Brioli, Annamaria, primary, Lomaia, Elza, additional, Fabisch, Christian, additional, Sacha, Tomasz, additional, Klamová, Hana, additional, Morozova, Elena, additional, Golos, Aleksandra, additional, Ernst, Philipp, additional, Olsson-Strömberg, Ulla, additional, Mayer, Jiri, additional, Nicolini, Franck E., additional, Bao, Han, additional, Castagnetti, Fausto, additional, Patkowska, Elzbieta, additional, Hirschbühl, Klaus, additional, Paczkowska, Edyta, additional, Parry, Anne, additional, Voskanyan, Astghik, additional, Saussele, Susanne, additional, Franke, Georg-Nikolaus, additional, Kiani, Alexander, additional, Faber, Edgar, additional, Lewandowski, Krzysztof, additional, Krause, Stefan W., additional, Dammann, Elke, additional, Anhut, Peter, additional, Gil, Justyna, additional, Südhoff, Thomas, additional, Heibl, Sonja, additional, Pfirrmann, Markus, additional, Hochhaus, Andreas, additional, and Lauseker, Michael, additional

Published
2022
Full Text
View/download PDF

50. Second tyrosine kinase inhibitor discontinuation attempt in patients with chronic myeloid leukemia

Author

Legros, Laurence, Nicolini, Franck E., Etienne, Gabriel, Rousselot, Philippe, Rea, Delphine, Giraudier, Stéphane, Guerci‐Bresler, Agnès, Huguet, Françoise, Gardembas, Martine, Escoffre, Martine, Ianotto, Jean‐Christophe, Noël, Marie‐Pierre, Varet, Bruno R., Pagliardini, Thomas, Touitou, Irit, Morisset, Stéphane, and Mahon, Francois‐Xavier

Published
2017
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results